---
title: "Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: NCT03459079"
description: "Formulary evidence on Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: NCT03459079. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 52 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence/nct03459079"
published: "2026-11-18T22:34:49-05:00"
modified: "2026-11-18T22:34:49-05:00"
---

# Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: NCT03459079

<a id="heading-3.1.4"></a>

## 3.1.4 NCT03459079

<a id="heading-3.1.4.1"></a>

### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

#### Aims stated in the ClinicalTrials.gov brief summary

> “The primary aim is to establish the safety, efficacy and mechanism of action of lanifibranor in patients with type 2 diabetes (T2DM) and nonalcoholic fatty liver disease (NAFLD). Specifically, to determine if lanifibranor decreases intrahepatic triglycerides (IHTG) (primary endpoint), improves hepatic insulin sensitivity, endogenous (hepatic) glucose production, de novo lipogenesis (DNL), HbA1c and lipid profiles.”

Source: [ClinicalTrials.gov NCT03459079](https://clinicaltrials.gov/study/NCT03459079)

<a id="topic-3.1.4.1-2"></a>

#### Aim stated in the published report

> “We tested its effect on insulin resistance (IR) at the level of different target tissues in relation to changes in intrahepatic triglyceride (IHTG) content.”
> “To this end, we examined the safety and efficacy of lanifibranor on intrahepatic triglyceride (IHTG) content and glucose/lipid metabolism using gold-standard imaging and metabolic measurements in patients with T2D and MASLD.”

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

<a id="topic-3.1.4.1-3"></a>

#### Hypothesis stated in the protocol

> “This study will test the hypothesis that treatment with lanifibranor will significantly decrease liver steatosis (primary endpoint) in patients with T2DM and NAFLD.”

Source: [University of Florida lanifibranor protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/79/NCT03459079/Prot_SAP_000.pdf)

<a id="heading-3.1.4.2"></a>

### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

#### Study dates and location in the ClinicalTrials.gov record

> “Study Start (Actual) 2018-08-14”
> “Primary Completion (Actual) 2023-04-18”
> “Study Completion (Actual) 2023-06-01”
> “This study has 1 location”
> “Gainesville, Florida, United States, 32610”

Source: [ClinicalTrials.gov NCT03459079](https://clinicaltrials.gov/study/NCT03459079)

<a id="topic-3.1.4.2-2"></a>

#### Results posting date in the ClinicalTrials.gov results

> “Results First Posted 2024-09-19”

Source: [ClinicalTrials.gov NCT03459079 results](https://clinicaltrials.gov/study/NCT03459079?tab=results)

<a id="topic-3.1.4.2-3"></a>

#### Site, recruitment sources, and enrollment period in the published report

> “The study was conducted at the University of Florida, Gainesville, Florida, in the United States and was approved by the Institutional Review Board.”
> “Participants were recruited from the general population of Gainesville, FL in response to newspaper and radio advertisements, or from the university endocrinology or primary care outpatient clinics (ClinicalTrials.gov identifier, NCT03459079).”
> “Between August 2018 and April 2023, 38 patients met the study eligibility criteria and were randomized to lanifibranor 800 mg/day (n = 20) or placebo (n = 18) and received at least one dose of study medication.”

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

<a id="heading-3.1.4.3"></a>

### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

#### Single-center, double-blind, placebo-controlled design in the published report

> “This single-center study was a double-blind, parallel-group, placebo-controlled, 24-week trial in 38 individuals with T2D.”
> “Patients were randomized (1:1) to 24 weeks of treatment with either 800 mg of oral lanifibranor or placebo once daily (with no stratification factor).”
> “Masking (blinding) was achieved by generating tablets with identical appearance. Participants, people giving the interventions, those assessing outcomes, and those analyzing the data were masked to group assignment.”

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

<a id="topic-3.1.4.3-2"></a>

#### Design details in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Interventional model description | “A two arm randomized (1:1), double-blind, placebo-controlled, trial.” |
| Masking | “Quadruple (ParticipantCare ProviderInvestigatorOutcomes Assessor)” |
| Phase | “Phase 2” |

Source: [ClinicalTrials.gov NCT03459079](https://clinicaltrials.gov/study/NCT03459079)

<a id="topic-3.1.4.3-3"></a>

#### Investigator-initiated design in the protocol

> “This study is a Phase II randomized, double-blind, placebo-controlled, single-center, investigator initiated, 24-week treatment study of lanifibranor in adult subjects with T2DM and NAFLD.”

Source: [University of Florida lanifibranor protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/79/NCT03459079/Prot_SAP_000.pdf)

<a id="topic-3.1.4.3-4"></a>

#### Run-in, treatment, and follow-up periods in the ClinicalTrials.gov record

> “The study will last 34-36 weeks (~6-8 weeks for run-in, 24 weeks of treatment and 4 weeks post-study follow-up), with an estimated recruitment period of ~9 months.”

Source: [ClinicalTrials.gov NCT03459079](https://clinicaltrials.gov/study/NCT03459079)

<a id="topic-3.1.4.3-5"></a>

#### Visits and end-of-treatment assessments in the published report

> “Participants were followed monthly after randomization and monitored throughout the study.”
> “All baseline measurements were repeated at the end of treatment (EOT), including routine chemistries, liver MRI (performed 3 to 7 days before EOT) and the euglycemic hyperinsulinemic clamp (i.e. insulin sensitivity study) at week 24. A final visit for safety assessment occurred approximately 28 days after the last dose of study drug.”

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

<a id="topic-3.1.4.3-6"></a>

#### Healthy control group for metabolic and imaging reference values

> “The study included a control group (n = 10, mean age 43 ± 18, 40% male, BMI 25.1 ± 3.3) of individuals without obesity, T2D or MASLD (<5% liver fat by 1H-MRS) to establish the normal range for the insulin sensitivity measurements.”

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

> “They are NOT treatment arms and participation ended after qualifying and the above studies.”

Source: [ClinicalTrials.gov NCT03459079 results](https://clinicaltrials.gov/study/NCT03459079?tab=results)

<a id="topic-3.1.4.3-7"></a>

#### Funding by Inventiva and role of the funder

> “Financial support provided by Inventiva Pharma.”
> “This study was designed by the principal investigator/corresponding author in agreement with and financially supported by Inventiva Pharma.”
> “The Research & Development [R&D] team at Inventiva Pharma had access to the database lock and assisted in the final analysis.”

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

<a id="heading-3.1.4.4"></a>

### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

#### Key inclusion and exclusion criteria in the published report

> “Key participant inclusion criteria were T2D with an IHTG content ≥10% by liver 1H-MRS (proton magnetic resonance spectroscopy); fasting plasma glucose ≥100 and ≤250 mg/dl; hemoglobin A1c (HbA1c) between 6.0% [42.1 mmol/mol] and ≤9.5% [80 mmol/mol]), despite the use of metformin monotherapy at a stable dose of ≥1,000 mg/day, or combination therapy with metformin ≥1,000 mg/day and other agents, including DPP-4 inhibitors, sulfonylurea, SGLT2 inhibitors, and/or GLP-1RAs at stable daily doses (and with stable body weight) for at least 12 weeks prior to screening.”
> “Patients with liver conditions other than MASLD or taking medications that could promote steatosis were excluded.”

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

<a id="topic-3.1.4.4-2"></a>

#### Key inclusion criteria in the ClinicalTrials.gov record

> “Have an age between 21 to 75 years inclusive”
> “Have uncontrolled diabetes with a fasting plasma glucose (FPG) ≥ 100 mg/dL but ≤ 250 mg/dL and HbA1c ≥ 6.0% but ≤ 9.5%, on diet alone, or on metformin (≥1,000 mg/day), and/or sulfonylurea and/or DPP-IV therapy, SGLT2 inhibitors or GLP1RA.”
> “Presence of hepatic steatosis (Intrahepatic Triglycerides IHTG) > 10 % determined by Magnetic Resonance and Spectroscopy (1H-MRS).”

Source: [ClinicalTrials.gov NCT03459079](https://clinicaltrials.gov/study/NCT03459079)

<a id="topic-3.1.4.4-3"></a>

#### Key exclusion criteria in the ClinicalTrials.gov record: other liver disease, alcohol, insulin or pioglitazone, CYP2C8 interacting drugs, and BMI

> “Evidence of liver disease other than NAFLD.”
> “History of excessive alcohol intake, defined by ≥ 21 units of alcohol per week in males and ≥14 units of alcohol per week in females for two years prior to enrollment”
> “Patients on insulin, pioglitazone (or prior use in the past 12 months).”
> “Treatment with strong inducers or inhibitors of CYP2C8, or treatment with substrates of CYP2B6 or CYP2C8.”
> “Body mass index (BMI) > 45 kg/m2.”

Source: [ClinicalTrials.gov NCT03459079](https://clinicaltrials.gov/study/NCT03459079)

<a id="topic-3.1.4.4-4"></a>

#### Population not selected for fibrosis stage F2 or higher

> “Another consideration was that the study did not seek to recruit patients with”
> “MASH (fibrosis stage ≥F2) or assess the role of improving IR on liver histology”
> “Adding a liver biopsy before and after 6 months of treatment to the in-depth metabolic evaluations performed would have added an unacceptable level of complexity for participants.”

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

<a id="heading-3.1.4.5"></a>

### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

#### Lanifibranor and placebo tablets in the ClinicalTrials.gov record

> “The film-coated tablet contains 400 mg of the active ingredient lanifibranor (IVA337) for an immediate release formulation. Participants receive 800mg/ day”
> “Film-coated tablets with a core containing 900 mg of a physical mixture of lactose monohydrate, microcrystalline cellulose, pre-gelatinized starch and magnesium stearate serve as placebo.”

Source: [ClinicalTrials.gov NCT03459079](https://clinicaltrials.gov/study/NCT03459079)

<a id="topic-3.1.4.5-2"></a>

#### Dose, administration with food, dose selection, and comparator in the protocol

> “The evaluated treatment will be as tablets of lanifibranor 400 mg, one dose of lanifibranor, 800 mg once a day (QD) versus placebo, i.e. two tablets (lanifibranor or indistinguishable placebo) per os, once daily, for 24 weeks. To improve bioavailability, drug intake is combined with food.”
> “The dose has been selected based on the available biomarker (adiponectin, HDL cholesterol, triglycerides) results in diabetes type 2 patients (Phase IIa study)”
> “Placebo is chosen as the comparator, as there is no licensed treatment for NAFLD/NASH.”
> “For obvious reasons, fibrates, as they are PPARα ligands, are not allowed, but dyslipidemias can be treated with statins, which are allowed.”

Source: [University of Florida lanifibranor protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/79/NCT03459079/Prot_SAP_000.pdf)

<a id="topic-3.1.4.5-3"></a>

#### Background antidiabetic therapy and run-in titration in the ClinicalTrials.gov record

> “These medicines will be continued at stable doses during the entire study.”
> “Subjects with an HbA1c > 8.0% but ≤ 9.5% will have their metformin (minimum dose required: 1,000 mg/day) maximized to 1,000 mg BID and/or glimepiride 2 mg once daily added during the first 2 weeks of the run-in period.”

Source: [ClinicalTrials.gov NCT03459079](https://clinicaltrials.gov/study/NCT03459079)

<a id="heading-3.1.4.6"></a>

### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

#### 3.1.4.6.1 Rationale for Using Intrahepatic Triglyceride Content by Proton Magnetic Resonance Spectroscopy as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

##### Primary endpoint as registered

> “Change in Intrahepatic Triglycerides (IHTG) Quantified by Proton Magnetic Resonance and Spectroscopy (¹H-MRS)”
> “Changes from baseline (Adjusted LS means) in absolute percent for change in intrahepatic triglycerides (IHTG) quantified by proton magnetic resonance and spectroscopy (¹H-MRS)are reported in each arms.”

Source: [ClinicalTrials.gov NCT03459079](https://clinicaltrials.gov/study/NCT03459079)

<a id="topic-3.1.4.6.1-2"></a>

##### Primary endpoint in the protocol and the published report

> “Primary outcome: Change in IHTG quantified by ¹H-MRS from baseline to 24 weeks”

Source: [University of Florida lanifibranor protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/79/NCT03459079/Prot_SAP_000.pdf)

> “The primary endpoint of the study was the change in IHTG content measured by 1H-MRS from baseline to EOT.”

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

<a id="topic-3.1.4.6.1-3"></a>

##### Proton magnetic resonance spectroscopy as the reference imaging method

> “The diagnosis of NAFLD on imaging will be done by measuring IHTG using the gold-standard magnetic resonance and spectroscopy (¹H-MRS) technique.”

Source: [ClinicalTrials.gov NCT03459079](https://clinicaltrials.gov/study/NCT03459079)

<a id="topic-3.1.4.6.1-4"></a>

##### Thresholds for liver fat response and resolution and their assumed relation to histology in the protocol

> “reduction in liver fat by ¹H-MRS is empiric as there are no studies (except the Belfort et al, NEJM 2006 (1) and Cusi et al (2) with pioglitazone) comparing simultaneously ¹H-MRS data with liver histology, but it is assumed that such threshold is likely to correlate with positive histological changes in NASH, based on the investigator's experience.”
> “Proportion of patients considered as having resolution of NAFLD (≤5.5% IHTG quantified by 1H- MRS) at 24 weeks (highly likely to translate into histological benefit in NASH).”

Source: [University of Florida lanifibranor protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/79/NCT03459079/Prot_SAP_000.pdf)

<a id="topic-3.1.4.6.1-5"></a>

##### Relation of steatosis to insulin resistance and to histological response in the published report

> “More importantly, steatosis is more strongly associated with IR than fibrosis in MASLD”
> “The ∼50% reduction in hepatic steatosis is consistent with the histological improvement reported in a prior 6-month study of identical duration”
> “The study focus was examining the role of panPPAR agonism on upstream metabolic aspects of the disease, and not liver histology for which it was not statistically powered.”

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

<a id="topic-3.1.4.6.1-6"></a>

##### Secondary endpoints: insulin sensitivity by clamp, IHTG response, cardiometabolic parameters, and liver stiffness

> “The main prespecified secondary endpoint was the change in hepatic, muscle and adipose tissue insulin sensitivity using the gold-standard euglycemic hyperinsulinemic clamp technique to measure glucose turnover. Other secondary endpoints included changes in cardiometabolic parameters (i.e., HbA1c, lipid profile, adiponectin).”
> “Secondary outcomes included proportion of patients without steatosis after treatment (IHTG <5.5%) and proportion of patients with a ≥30% reduction in IHTG.”

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

> “Changes in Hepatic Fibrosis (Liver Stiffness Measurement by Vibration Controlled Transient Elastography in kPa) on Imaging.”
> “Changes in Hepatic Fibrosis (Liver Stiffness Measurement by Magnetic Resonance Elastography in kPa) on Imaging.”

Source: [ClinicalTrials.gov NCT03459079](https://clinicaltrials.gov/study/NCT03459079)

<a id="heading-3.1.4.7"></a>

### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

#### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

##### Planned sample size revised on the basis of NATIVE steatosis results in the protocol

> “Version 2.4.1. Statistical analysis modified (number of patients reduced based on the results from NATIVE on steatosis [primary endpoint in this trial])”
> “In NATIVE, the proportion of patients with a reduction in steatosis to lanifibranor was 73% versus 26% with placebo (steatosis being the primary endpoint of this study)”
> “This represents a change of ≥7.0% with lanifibranor versus the control group. The expected standard deviation of the change from baseline is expected to be 7%.”
> “Considering a type I error of 0.05 (2-sided), a power of 0.80, an allocation ratio of 1:1, the same variance in both treatment groups and a parametric test of mean comparison, the required sample size per group is 15 patients to complete treatment.”
> “Assuming that 10 % of randomized patients will not complete the trial, the total number of patients to be randomized is 33-34 patients.”

Source: [University of Florida lanifibranor protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/79/NCT03459079/Prot_SAP_000.pdf)

<a id="topic-3.1.4.7.1-2"></a>

##### Reduction of the planned number of participants stated in the ClinicalTrials.gov results

> “The original number of patients to be recruited was reduced during the trial based on the results of the NATIVE study (Francque et al, N Engl J Med. 2021 Oct 21;385(17):1547-1558. doi: 10.1056/NEJMoa2036205), as explained in the study protocol.”

Source: [ClinicalTrials.gov NCT03459079 results](https://clinicaltrials.gov/study/NCT03459079?tab=results)

<a id="topic-3.1.4.7.1-3"></a>

##### Registry actual enrollment of 128 and 38 randomized participants

> “Enrollment (Actual) 128”

Source: [ClinicalTrials.gov NCT03459079](https://clinicaltrials.gov/study/NCT03459079)

> “Of 128 total enrolled participants, 38 subjects with type 2 diabetes met inclusion criteria and were randomized to be treated. 10 healthy controls met inclusion criteria and completed imaging and other study assessments.”

Source: [ClinicalTrials.gov NCT03459079 results](https://clinicaltrials.gov/study/NCT03459079?tab=results)

<a id="topic-3.1.4.7.1-4"></a>

##### Randomized participants, full analysis set, and completers in the published report and the poster

> “Of the 38 individuals randomized, 28 completed the 24-week study (lanifibranor [n = 14, 70%] and placebo [n = 14, 78%]).”
> “Similar results were observed in a sensitivity analysis among completers [n = 28]”

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

> “LS=Least Square, FAS=Full Analysis Set (n=38); Completers (n=28, 14 per group)”

Source: [Barb et al. (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/AASLD-abstract-3.pdf)

<a id="topic-3.1.4.7.1-5"></a>

##### Randomized participants in the company topline release

> “The Phase II clinical trial randomized 38 patients into two arms, with patients receiving placebo or treatment with lanifibranor at 800mg/day for 24 weeks.”

Source: [Inventiva University of Florida trial topline release (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Cusi-Lani-Topline-Results-EN-06132023-1.pdf)

<a id="heading-3.1.4.7.2"></a>

#### 3.1.4.7.2 Description of Analysis Sets

<a id="topic-3.1.4.7.2-1"></a>

##### Analysis sets defined in the protocol

> “The full analysis set consists of all randomized patients who received at least one dose of the assigned treatment.”
> “This set is the primary set of patients used in the primary analysis of the primary efficacy endpoint.”
> “The set of evaluable patients will consist of the FAS after exclusion of all patients who did not have an efficacy evaluation (IHTG) at week 24.”
> “This set is composed of all patients who completed the treatment and the study and who were free from major protocol deviation that can bias the estimation of the treatment effect at week 24.”
> “The safety set of patients will include all patients who have taken at least one dose of treatment (IVA 337 or placebo), regardless any protocol deviations.”

Source: [University of Florida lanifibranor protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/79/NCT03459079/Prot_SAP_000.pdf)

<a id="topic-3.1.4.7.2-2"></a>

##### Analysis sets, statistical tests, multiplicity, and missing data in the published report

> “Analyses were conducted on the full analysis set (FAS), including all randomized patients that received at least one dose of the assigned regimen.”
> “For statistical tests, the type I error risk was set at 5% (two-sided) in accordance with the protocol. No pre-specified plan was defined in the protocol to control for multiplicity adjustment for secondary or exploratory endpoints, which are considered exploratory.”
> “Categorical parameters were compared between treatment groups using Chi2 or Fisher’s exact tests.”
> “For the primary analysis, the primary rule for handling missing IHTG data at Week 24 was to use the baseline value at Week 24 if the mean change from baseline in the placebo group was equal to zero or was an improvement, or if the reason for missing data was definitely not related to treatment or disease progression.”
> “For categorical parameters, missing data were imputed as a failure.”

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

<a id="heading-3.1.4.8"></a>

### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

#### 3.1.4.8.1 Participant Disposition

<a id="topic-3.1.4.8.1-1"></a>

##### Participant flow by group in the ClinicalTrials.gov results

> “Arm/Group Title Lanifibranor Arm Placebo Healthy Control Group (Not a Treatment Arm)”
> “Started 20 18 10”
> “Completed 14 14 10”
> “Not Completed 6 4 0”
> “Adverse Event 4 2 0”
> “Withdrawal by Subject 2 2 0”
> “This study was performed during the epidemic of COVID that greatly impacted recruitment and promoted dropout.”

Source: [ClinicalTrials.gov NCT03459079 results](https://clinicaltrials.gov/study/NCT03459079?tab=results)

<a id="topic-3.1.4.8.1-2"></a>

##### Completion and reasons for discontinuation in the published report

> “Of the 38 individuals randomized, 28 completed the 24-week study (lanifibranor [n = 14, 70%] and placebo [n = 14, 78%]). Reasons for premature treatment discontinuation were adverse events (two participants in the placebo group and four in the lanifibranor group) and consent withdrawal (two in each group, during the COVID-19 pandemic).”

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

<a id="heading-3.1.4.8.2"></a>

#### 3.1.4.8.2 Baseline Characteristics

<a id="topic-3.1.4.8.2-1"></a>

##### Baseline clinical and laboratory characteristics, FAS (published report)

> “Baseline clinical and laboratory characteristics (FAS, N = 38).”
> “Participants were well matched for age, gender, race, BMI; routine chemistries, glycemic control and baseline IHTG content were also well matched between the two groups.”

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

| Characteristic | Placebo (n = 18) | Lanifibranor (n = 20) |
| --- | --- | --- |
| Age, years (mean ± SD) | “58 ± 11” | “61 ± 7” |
| Gender (% male/female) | “28/72” | “45/55” |
| White, n (%) | “15 (83%)” | “18 (90%)” |
| Weight, kg (mean ± SD) | “99 ± 20” | “96 ± 14” |
| Body mass index, kg/m2 (mean ± SD) | “34.3 ± 6.2” | “33.8 ± 5.1” |
| Fasting plasma glucose, mg/dl (mean ± SD) | “122 ± 22” | “130 ± 26” |
| HbA1c, % (mean ± SD) | “7.0 ± 0.8” | “6.8 ± 0.5” |
| Fasting plasma insulin, μU/ml (mean ± SD) | “18.2 ± 12.7” | “16.4 ± 8.6” |
| Triglycerides, mg/dl (mean ± SD) | “196 ± 101” | “175 ± 95” |
| HDL-C, mg/dl (mean ± SD) | “43 ± 12” | “42 ± 9” |
| Alanine aminotransferase, U/L (mean ± SD) | “35 ± 27” | “37 ± 20” |
| Aspartate aminotransferase, U/L (mean ± SD) | “31 ± 19” | “31 ± 14” |
| HOMA-IR (mean ± SD) | “5.4 ± 3.4” | “5.6 ± 3.2” |
| Adiponectin, μg/ml (mean ± SD) | “5.0 ± 3.7” | “4.5 ± 2.8” |
| Intrahepatic triglyceride content, % (mean ± SD) | “18 ± 7” | “21 ± 7” |
| Liver stiffness by MRE, kPa (mean ± SD) | “2.5 ± 1.1” | “2.8 ± 0.8” |

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

<a id="topic-3.1.4.8.2-2"></a>

##### Mean baseline HbA1c stated in the discussion of the published report

> “Most patients in this study had mild hyperglycemia (mean baseline HbA1c was 7.2%), so the full potential of lanifibranor to induce a greater glucose-lowering effect in patients with higher mean plasma glucose levels remains to be investigated.”

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

<a id="topic-3.1.4.8.2-3"></a>

##### Baseline cT1, CAP, and LSM (poster)

> “CAP= Control Attenuation Parameter, LSM= Liver Stiffness Measurement.”

Source: [Barb et al. (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/AASLD-abstract-3.pdf)

| Characteristic | Lanifibranor (N=20) | Placebo (N=18) |
| --- | --- | --- |
| Baseline corrected T1 mapping, ms | “887 ± 72” | “924 ± 116” |
| Baseline CAP, db/m | “356 ± 36” | “352 ± 28” |
| Baseline LSM, kPa | “8.3 ± 4.6” | “8.2 ± 7.2” |

Source: [Barb et al. (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/AASLD-abstract-3.pdf)

<a id="heading-3.1.4.8.3"></a>

#### 3.1.4.8.3 Efficacy Results

<a id="topic-3.1.4.8.3-1"></a>

##### Primary endpoint: absolute change in IHTG at week 24, FAS and completers (published report)

> “The primary endpoint was met: treatment with lanifibranor was associated with a statistically significant absolute decrease in liver fat content (IHTG) by the end of the treatment period compared to placebo: FAS [n = 38]: -8.7% vs. -3.0%, respectively; least squares [LS] mean difference -5.6%, 95% CI -9.6 to -1.7%, p = 0.007 (Table 2, Fig. 2A). Similar results were observed in a sensitivity analysis among completers [n = 28] -10.8% vs. -4.0%; LS mean difference -6.9%, 95% CI -10.8 to -2.9%, p = 0.001 (Table 2, Fig. 2B).”

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

<a id="topic-3.1.4.8.3-2"></a>

##### Relative change in IHTG, IHTG reduction of at least 30%, and steatosis resolution, FAS and completers (published report)

> “The relative percent change in liver fat content significantly decreased more with lanifibranor compared to placebo (FAS [n = 38]: -44% vs. -12%, respectively; LS means difference -31%, 95% CI -51 to -12, p = 0.002) (Fig. 2C, Table 2).”
> “In completers [n = 28] (Fig. 2C, Table 2), the reduction in IHTG was -50% with lanifibranor vs. -16% with placebo (LS means difference -33%, 95% CI -53 to -14, respectively; p = 0.002).”
> “More patients achieved a ≥30% reduction in IHTG with lanifibranor compared to placebo (FAS 65% vs. 22%; completers 79% vs. 29%; both p <0.01, Fig. 2D, Table 2), as well as steatosis resolution (IHTG ≤5.5%) by the end of the treatment period (FAS 25% vs. 0%; completers 21% vs. 0%; both p <0.05, Table 2).”

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

<a id="topic-3.1.4.8.3-3"></a>

##### IHTG endpoints at week 24 (registry)

> “We report absolute change from baseline in LS mean [95% CI]”

Source: [ClinicalTrials.gov NCT03459079 results](https://clinicaltrials.gov/study/NCT03459079?tab=results)

| Outcome | Lanifibranor (n = 20) | Placebo (n = 18) |
| --- | --- | --- |
| Absolute change in IHTG, LS mean (95% CI) | “-8.7 (-11.3 to -6.0)” | “-3.0 (-5.9 to -0.2)” |
| IHTG decrease of ≥30%, % of participants (95% CI) | “65 (41 to 85)” | “22 (6 to 48)” |
| NAFLD resolution (IHTG ≤5.5%), % of participants (95% CI) | “25 (9 to 49)” | “0 (0 to 19)” |

Source: [ClinicalTrials.gov NCT03459079 results](https://clinicaltrials.gov/study/NCT03459079?tab=results)

<a id="topic-3.1.4.8.3-4"></a>

##### Secondary metabolic endpoints at week 24, FAS adjusted LS means (published report)

> “Effect of lanifibranor on metabolic parameters after 24 weeks of treatment.”
> “In the FAS, missing data were imputed using the last observation carried forward method.”

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

| Endpoint, FAS | Lanifibranor, adjusted LS mean [95% CI] | Placebo, adjusted LS mean [95% CI] | Adjusted LS mean difference [95% CI] | p value |
| --- | --- | --- | --- | --- |
| Fasting hepatic glucose production, relative change (%) | “-8 [-13; -4]” | “4 [-1; 9]” | “-13 [-20; -6]” | “<0.001” |
| Hepatic IR index, relative change (%) | “-26 [-37; -14]” | “-7 [-19; 4]” | “-18 [-34; -2]” | “0.04” |
| Insulin-stimulated muscle glucose disposal, relative change (%) | “30 [13; 46]” | “0 [-17; 18]” | “29 [5; 54]” | “0.02” |
| Fasting plasma insulin, absolute change (μU/ml) | “-3.1 [-5.5; -0.8]” | “-0.0 [-2.5; 2.5]” | “-3.1 [-6.5; 0.3]” | “0.07” |
| Fasting plasma glucose, absolute change (mg/dl) | “-17.2 [-27.4; -7.0]” | “2.4 [-8.4; 13.2]” | “-19.6 [-34.5; -4.7]” | “0.01” |
| HOMA-IR, absolute change | “-1.6 [-2.5; -0.7]” | “-0.1 [-1.1; 0.8]” | “-1.5 [-2.8; -0.2]” | “0.03” |
| Adipo-IR, absolute change | “-2.7 [-4.3; -1.2]” | “-0.7 [-2.4; 0.9]” | “-2.0 [-4.2; 0.3]” | “0.08” |
| HbA1c, absolute change (%) | “-0.7 [-1.0; -0.5]” | “-0.1 [-0.3; 0.2]” | “-0.6 [-1.0; -0.5]” | “<0.001” |
| HDL-C, absolute change (mg/dl) | “7.6 [4.4; 10.7]” | “0.9 [-2.4; 4.3]” | “6.6 [2.0; 11.3]” | “0.006” |
| Adiponectin, fold change | “2.4 [2.0; 2.7]” | “1.0 [0.6; 1.4]” | “1.4 [0.9; 1.9]” | “<0.001” |

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

<a id="topic-3.1.4.8.3-5"></a>

##### Hepatic glucose production and muscle glucose disposal, completers (published report)

> “Among completers, the mean ± standard error fasting HGP decreased significantly with lanifibranor from 3.98 ± 0.23 to 3.34 ± 0.19 mg/kg/min compared to an increase with placebo (3.69 ± 0.23 to 3.87 ± 0.18 mg/kg/min), with a mean relative difference vs. placebo at week 24 of -16%, p <0.001 (Table 2, Fig. 3A).”
> “Tissue Rd increased by approximately 45% with lanifibranor compared to placebo (LS means difference 45%, 95% CI 12 to 77; Table 2, Fig. 3C).”

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

<a id="topic-3.1.4.8.3-6"></a>

##### Liver stiffness by transient elastography and MRE and plasma cytokeratin-18 at week 24 (registry)

> “Two subjects in the lanifibranor group missing this measurement due to technical errors”

Source: [ClinicalTrials.gov NCT03459079 results](https://clinicaltrials.gov/study/NCT03459079?tab=results)

| Outcome | Lanifibranor | Placebo |
| --- | --- | --- |
| Liver stiffness by vibration controlled transient elastography, absolute change in kPa, LS mean (95% CI); n = 20 and 18 | “-1.49 (-2.66 to -0.31)” | “-0.34 (-1.57 to 0.9)” |
| Liver stiffness by MRE, change in kPa, LS mean (95% CI); n = 18 and 18 | “0.23 (0.03 to 0.42)” | “-0.06 (-0.25 to 0.13)” |
| Plasma cytokeratin 18, absolute change in IU/L, mean (SD); n = 20 and 18 | “-130.71(164.28)” | “-70.21(230.39)” |

Source: [ClinicalTrials.gov NCT03459079 results](https://clinicaltrials.gov/study/NCT03459079?tab=results)

> “The trend in improvement of steatohepatitis disease activity by liver cT1 and liver stiffness measurement was consistent with NATIV2 (Table S3).”

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

<a id="topic-3.1.4.8.3-7"></a>

##### Primary endpoint as reported in the 2023 congress poster, FAS and completers

> “Late Breaking Poster Abstract # 48475 at The Liver Meeting 2023, Boston, MA, USA”
> “Figure 3: Lanifibranor compared to placebo significantly lowered IHTG at EOT: in FAS the absolute change in IHTG as -10.1% in lanifibranor vs. -1.4% in placebo; least squares [LS] means difference -5.6%, [95% CI -9.6 to -1.7%], p=0.007; completers -12.4% vs. -2.4%; LS means difference -6.9%, [95% CI -10.8 to -2.9%], p=0.001 (Figure 3A and 3B).”

Source: [Barb et al. (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/AASLD-abstract-3.pdf)

<a id="topic-3.1.4.8.3-8"></a>

##### Topline results, FAS and completers (company release, June 2023)

> “Lanifibranor 800mg achieved the primary efficacy endpoint demonstrating a 44% reduction of hepatic fat measured by proton magnetic resonance spectroscopy (1H-MRS) following 24 weeks of treatment in patients with nonalcoholic fatty liver disease (NAFLD).”
> “The study demonstrated a statistically significant higher proportion of patients achieving a greater than 30% liver triglyceride reduction (65% vs. 22%, p =0.008) as well as NAFLD resolution (25% vs. 0%, p = 0.048) defined as IHTG ≤ 5.5% at week 24, with lanifibranor compared to placebo.”
> “Full Analysis Set (N=38)”
> “Completers (N=28)”
> “June 13, 2023”

Source: [Inventiva University of Florida trial topline release (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Cusi-Lani-Topline-Results-EN-06132023-1.pdf)

| Completers, change from baseline to week 24 | Placebo (n=14) | Lanifibranor 800 mg (n=14) |
| --- | --- | --- |
| Absolute change in HbA1c, % | “-0.2%” | “-0.9” |
| Absolute change in fasting plasma insulin, μU/ml | “-1.0” | “-6.7” |
| Absolute change in hepatic insulin resistance index | “-9.5” | “-30.1” |
| Absolute change in basal endogenous glucose production (mg/kgLBM/min) | “0.1” | “-0.5” |
| Absolute change in muscle insulin-stimulated glucose disposal (mg/kg LBM/min) | “-0.2” | “+2.2” |
| Absolute change in HDL-C, mg/dl | “-0.3” | “6.3” |
| Absolute change in adiponectin, μg/mL | “-0.2” | “7.5” |

Source: [Inventiva University of Florida trial topline release (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Cusi-Lani-Topline-Results-EN-06132023-1.pdf)

<a id="heading-3.1.4.8.4"></a>

#### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.4.8.5"></a>

#### 3.1.4.8.5 Safety Results

<a id="topic-3.1.4.8.5-1"></a>

##### Weight gain, adverse events, and discontinuations (published report)

> “Compared to placebo, lanifibranor caused weight gain (Fig. S5). Mean weight gain was +2.7% under lanifibranor compared to -1.0% on placebo at the end of the treatment period.”
> “Adverse events were mostly mild (anemia and gastrointestinal side effects) and balanced between groups. Six patients prematurely discontinued study drug due to adverse events (Table 3). One serious adverse event (COVID-19 infection and hospitalization with pulmonary embolism) occurred under lanifibranor but was unrelated to study drug.”
> “Five were drug-related treatment-emergent adverse events: two in the placebo group (one severe elevation in plasma aminotransferases of unknown etiology, another an asymptomatic elevation of lipase level), and three in the lanifibranor group: asymptomatic elevation of lipase level (n = 1), leukopenia (n = 1) and drug intolerance (nausea, headache, loose stools, atypical chest pain).”
> “Lanifibranor was safe and well tolerated, with no patient developing a drug-related serious adverse event.”

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

<a id="topic-3.1.4.8.5-2"></a>

##### Treatment-emergent adverse events by group (published report)

| Event, n (%) | Placebo (n = 18) | Lanifibranor (n = 20) |
| --- | --- | --- |
| Patients with TEAEs | “17 (94%)” | “18 (90%)” |
| Patients with severe TEAEs | “0 (0%)” | “1 (5%)” |
| Patients with serious adverse events | “0 (0%)” | “1 (5)” |
| TEAEs leading to drug discontinuation | “2 (11%)” | “4 (20%)” |
| Drug-related TEAE leading to discontinuation | “2 (11%)” | “3 (15%)” |
| Diarrhea | “3 (17%)” | “5 (25%)” |
| Elevated lipase level | “3 (17%)” | “5 (25%)” |
| Anemia | “2 (11%)” | “4 (20%)” |
| Leukopenia | “1 (6%)” | “3 (15%)” |
| Headache | “1 (6%)” | “3 (15%)” |
| Arthralgia | “3 (17%)” | “0 (0%)” |
| Oedema | “0 (0%)” | “1 (5%)” |
| Hypoglycemia | “0 (0%)” | “1 (5%)” |
| Decrease in eGFR | “2 (11%)” | “1 (5%)” |

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

<a id="topic-3.1.4.8.5-3"></a>

##### Weight change in kilograms, edema, hemoglobin, and lipase (poster)

> “Compared to placebo, lanifibranor caused weight gain of +2.7% (+2.5 ± 3.1 kg vs -1.2 ± 2.6 kg in placebo, p=0.002) and in 1 patient mild edema.”
> “Changes in hemoglobin levels by week 24 were mild.”
> “Although elevated lipase was reported more commonly in lanifibranor group, none were associated with clinical symptoms.”

Source: [Barb et al. (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/AASLD-abstract-3.pdf)

<a id="topic-3.1.4.8.5-4"></a>

##### Mortality, serious adverse events, and selected other adverse events over 28 weeks (registry)

> “Time Frame 28 weeks”

Source: [ClinicalTrials.gov NCT03459079 results](https://clinicaltrials.gov/study/NCT03459079?tab=results)

| Event, affected / at risk (%) | Lanifibranor | Placebo |
| --- | --- | --- |
| All-cause mortality | “0/20 (0.00%)” | “0/18 (0.00%)” |
| Serious adverse events, total | “1/20 (5.00%)” | “0/18 (0.00%)” |
| Other (not including serious) adverse events, total | “18/20 (90.00%)” | “17/18 (94.44%)” |
| Anaemia | “4/20 (20.00%)” | “2/18 (11.11%)” |
| Diarrhoea | “5/19 (26.32%)” | “3/18 (16.67%)” |
| Elevated lipase level | “5/20 (25.00%)” | “3/18 (16.67%)” |
| Edema | “1/20 (5.00%)” | “0/18 (0.00%)” |

Source: [ClinicalTrials.gov NCT03459079 results](https://clinicaltrials.gov/study/NCT03459079?tab=results)

<a id="heading-3.1.4.9"></a>

### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

#### Summary: design, sample size, and enrolled population

- The trial was single-center (Gainesville, Florida) and investigator-initiated, with financial support from Inventiva; the Inventiva research and development team had access to the database lock and assisted in the final analysis.
- The planned number of participants was reduced during the trial on the basis of NATIVE steatosis results, to 15 per group completing treatment (power 0.80) and 33 to 34 randomized. A total of 38 participants were randomized (20 lanifibranor, 18 placebo), and 28 completed 24 weeks (14 [70%] and 14 [78%]). The registry states that the COVID epidemic greatly impacted recruitment and promoted dropout. The registry enrollment of 128 counts all enrolled participants, of whom 38 were randomized and 10 were healthy controls.
- The registry gave an estimated recruitment period of about 9 months; randomization took place between August 2018 and April 2023.
- The authors state that the study did not seek to recruit patients with MASH (fibrosis stage ≥F2) or to assess the role of improving insulin resistance on liver histology, for which the study was “not statistically powered”. The protocol states that the liver fat thresholds are assumed to correlate with histological changes based on the investigator's experience.
- The discussion of the published report describes mild hyperglycemia with a mean baseline HbA1c of 7.2%; the baseline table gives 7.0 ± 0.8% with placebo and 6.8 ± 0.5% with lanifibranor. The male/female percentages at baseline were 28/72 with placebo and 45/55 with lanifibranor.

Source: [ClinicalTrials.gov NCT03459079](https://clinicaltrials.gov/study/NCT03459079); [University of Florida lanifibranor protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/79/NCT03459079/Prot_SAP_000.pdf); [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext); [ClinicalTrials.gov NCT03459079 results](https://clinicaltrials.gov/study/NCT03459079?tab=results)

<a id="topic-3.1.4.9-2"></a>

#### Summary: missing-data handling, multiplicity, and figures that differ by source

- For missing week 24 IHTG data, the primary analysis used the baseline value under stated conditions; missing categorical data were imputed as failure, and missing data for the secondary metabolic endpoints were imputed by last observation carried forward.
- The protocol defined no plan to control multiplicity for secondary or exploratory endpoints, which are considered exploratory.
- The absolute change in IHTG differs by source. The 2023 congress poster reports -10.1% with lanifibranor versus -1.4% with placebo in the FAS and -12.4% versus -2.4% in completers; the published report gives -8.7% versus -3.0% (FAS) and -10.8% versus -4.0% (completers), and the registry gives -8.7 and -3.0. Both the poster and the published report give LS mean differences of -5.6% (FAS) and -6.9% (completers).

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext); [Barb et al. (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/AASLD-abstract-3.pdf); [ClinicalTrials.gov NCT03459079 results](https://clinicaltrials.gov/study/NCT03459079?tab=results)

## Related pages
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Terms and abbreviations](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations.md)
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product information and disease description](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical evidence](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic information and modeling report](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: References](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references.md)
